Neoadjuvant chemotherapy plus pembrolizumab vs chemotherapy alone for patients with early and advanced triple-negative breast cancer (TNBC): Outcomes from Berkshire Cancer Centre

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical oncology Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI:10.1016/j.clon.2025.104026

Ismini Tsagkaraki, Anil Babar, Madhumita Bhattacharyya

引用次数: 0

查看原文本刊更多论文

早期和晚期三阴性乳腺癌（TNBC）患者的新辅助化疗联合派姆单抗与单独化疗：来自伯克希尔癌症中心的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical oncology 医学-肿瘤学

CiteScore

5.20

自引率

8.80%

发文量

332

审稿时长

40 days

期刊介绍： Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.